Long‐term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study

A prospective multicenter Phase II study was performed to examine the efficacy and safety of imatinib therapy in newly diagnosed Japanese patients with chronic‐phase CML. Patients were scheduled to receive imatinib 400 mg daily. Plasma imatinib concentrations were measured by liquid chromatography–t...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Sci
Auteurs principaux: Ohnishi, Kazunori, Nakaseko, Chiaki, Takeuchi, Jin, Fujisawa, Shin, Nagai, Tadashi, Yamazaki, Hirohito, Tauchi, Tetsuzo, Imai, Kiyotoshi, Mori, Naoki, Yagasaki, Fumiharu, Maeda, Yasuhiro, Usui, Noriko, Miyazaki, Yasushi, Miyamura, Koichi, Kiyoi, Hitoshi, Ohtake, Shigeki, Naoe, Tomoki
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2012
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7685081/
https://ncbi.nlm.nih.gov/pubmed/22364419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2012.02253.x
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires